Compare RVSN & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RVSN | ENVB |
|---|---|---|
| Founded | 2016 | 1994 |
| Country | Israel | United States |
| Employees | 47 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0M | 8.1M |
| IPO Year | N/A | 2000 |
| Metric | RVSN | ENVB |
|---|---|---|
| Price | $4.55 | $1.34 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 16.2K | ★ 101.4K |
| Earning Date | 03-31-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $39,914,675.00 |
| Revenue This Year | $860.32 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.17 | $0.56 |
| 52 Week High | $9.39 | $13.25 |
| Indicator | RVSN | ENVB |
|---|---|---|
| Relative Strength Index (RSI) | 45.25 | 34.76 |
| Support Level | $4.60 | $0.60 |
| Resistance Level | $5.09 | $1.58 |
| Average True Range (ATR) | 0.31 | 0.11 |
| MACD | 0.09 | 0.03 |
| Stochastic Oscillator | 51.03 | 18.79 |
Rail Vision Ltd is an early commercialization stage technology company focused on railway safety systems using AI-integrated sensing systems. The company develops and commercializes proprietary, multi-spectral electro-optic platforms that provide extended-range situational awareness and real-time hazard detection. Using machine learning algorithms to identify and classify obstacles, the company's technology enhances safety, improves operational efficiency, and supports continuity across deployments.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.